Trial of Controversial Alzheimer’s Drug Halted After Disappointing Results
Health
By Teddy Rosenbluth from NYT Health https://ift.tt/2h0KB9E
via IFTTT your-feed-science, Falsification of Data, Clinical Trials, Regulation and Deregulation of Industry, Alzheimer's Disease, Decisions and Verdicts, Research, Securities and Commodities Violations Cassava Sciences said that its drug did not significantly reduce cognitive decline in 1,900 people with mild to moderate Alzheimer’s disease.

By Teddy Rosenbluth from NYT Health https://ift.tt/2h0KB9E
via IFTTT your-feed-science, Falsification of Data, Clinical Trials, Regulation and Deregulation of Industry, Alzheimer's Disease, Decisions and Verdicts, Research, Securities and Commodities Violations Cassava Sciences said that its drug did not significantly reduce cognitive decline in 1,900 people with mild to moderate Alzheimer’s disease.
Comments
Post a Comment